- Home
- BAFN vs NVNO Comparison
BAFN vs NVNO Comparison
Compare BAFN & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- NVNO
- Stock Information
- Founded
- BAFN 1999
- NVNO 1987
- Country
- BAFN United States
- NVNO United States
- Employees
- BAFN N/A
- NVNO N/A
- Industry
- BAFN Savings Institutions
- NVNO Medical/Dental Instruments
- Sector
- BAFN Finance
- NVNO Health Care
- Exchange
- BAFN Nasdaq
- NVNO Nasdaq
- Market Cap
- BAFN 70.2M
- NVNO 61.9M
- IPO Year
- BAFN N/A
- NVNO N/A
- Fundamental
- Price
- BAFN $14.10
- NVNO $2.45
- Analyst Decision
- BAFN
- NVNO
- Analyst Count
- BAFN 0
- NVNO 0
- Target Price
- BAFN N/A
- NVNO N/A
- AVG Volume (30 Days)
- BAFN 11.1K
- NVNO 94.7K
- Earning Date
- BAFN 04-24-2025
- NVNO 05-07-2025
- Dividend Yield
- BAFN 2.28%
- NVNO N/A
- EPS Growth
- BAFN 134.31
- NVNO N/A
- EPS
- BAFN 2.62
- NVNO N/A
- Revenue
- BAFN $83,769,000.00
- NVNO N/A
- Revenue This Year
- BAFN N/A
- NVNO N/A
- Revenue Next Year
- BAFN N/A
- NVNO $409.09
- P/E Ratio
- BAFN $5.35
- NVNO N/A
- Revenue Growth
- BAFN 10.60
- NVNO N/A
- 52 Week Low
- BAFN $10.40
- NVNO $2.03
- 52 Week High
- BAFN $19.75
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- BAFN 35.32
- NVNO 44.81
- Support Level
- BAFN $13.00
- NVNO $2.05
- Resistance Level
- BAFN $14.25
- NVNO $2.44
- Average True Range (ATR)
- BAFN 1.16
- NVNO 0.23
- MACD
- BAFN -0.23
- NVNO 0.02
- Stochastic Oscillator
- BAFN 20.75
- NVNO 53.42
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).